Breaking Immunotherapy Resistance in Melanoma: The Role of Oncolytic Virus RP1

Anti-PD-1-resistant melanoma shows a 32.9% response rate, 15% complete response, and a median response duration of 33.7 months with RP1 + nivolumab

Prof. Dr. Mustafa Özdoğan
Breaking Immunotherapy Resistance in Melanoma: The Role of Oncolytic Virus RP1